Buchumschlag

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Lif...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Tresckow, Bastian von (VerfasserIn) , Fanale, Michelle (VerfasserIn) , Ardeshna, Kirit M. (VerfasserIn) , Chen, Robert W. (VerfasserIn) , Meißner, Julia (VerfasserIn) , Morschhauser, Franck (VerfasserIn) , Moskowitz, Craig H. (VerfasserIn) , Zinzani, Pier Luigi (VerfasserIn) , Giezek, Hilde (VerfasserIn) , Balakumaran, Arun (VerfasserIn) , Vo, Thao T. (VerfasserIn) , Rauthe, Monika Sabine (VerfasserIn) , Brice, Pauline (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 23 Apr 2019
In: Leukemia and lymphoma
Year: 2019, Jahrgang: 60, Heft: 11, Pages: 2705-2711
ISSN:1029-2403
DOI:10.1080/10428194.2019.1602262
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/10428194.2019.1602262
Volltext
Verfasserangaben:Bastian von Tresckow, Michelle Fanale, Kirit M. Ardeshna, Robert Chen, Julia Meissner, Franck Morschhauser, Craig Moskowitz, Pier Luigi Zinzani, Hilde Giezek, Arun Balakumaran, Thao T. Vo, Monika Raut, & Pauline Brice
Beschreibung
Zusammenfassung:In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts.Clinicaltrials.gov identifier: NCT02453594.
Beschreibung:Gesehen am 16.04.2020
Beschreibung:Online Resource
ISSN:1029-2403
DOI:10.1080/10428194.2019.1602262

Ähnliche Einträge